Review and update of intraocular therapy in noninfectious uveitis

Current Opinion in Ophthalmology

Volumn 22, Issue 6, 2011, Pages 517-522

  Sallam, Ahmed ^a   Taylor, Simon R J ^b   Lightman, Sue ^b  

^a GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antivascular endothelial growth factor agents; corticosteroids; cystoid macular edema; methotrexate; noninfectious uveitis

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; METHOTREXATE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

CATARACT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; HUMAN; INTRAOCULAR PRESSURE; NONINFECTIOUS UVEITIS; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; SINGLE DRUG DOSE; UVEITIS;

GLUCOCORTICOIDS; HUMANS; UVEITIS;

EID: 80054913348     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834bbd68     Document Type: Review

References (75)

1. Androudi S, Letko E, Meniconi M, et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 2005; 13:205-212. (Pubitemid 41711292)
2. Angunawela RI, Heatley CJ, Williamson TH, et al. Intravitreal triamcinolone acetonide for refractory uveitic cystoid macular oedema: long term management and outcome. Acta Ophthalmol Scand 2005; 83:595-599. (Pubitemid 41488635)
3. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001; 108:765-772. (Pubitemid 32238474)
4. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112:1916 e1-1916 e7.
5. Sallam A, Comer RM, Chang JH, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 2008; 126:200-205. (Pubitemid 351240848)
6. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001; 29:2-6. (Pubitemid 32170788)
7. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122:336-340. (Pubitemid 38314193)
8. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112:593-598. (Pubitemid 41108858)
9. Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138:740-743. (Pubitemid 39452920)
10. Roth DB, Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009; 116:455-460.
11. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129:545-553.
12. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126:1191-1201.
13. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113:1020-1027. (Pubitemid 43795240)
14. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005; 112:1192-1198.
15. Mahajan VB, Gehrs KM, Goldstein DA, et al. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology 2009; 116:552 e1-557 e1.
16. Seth RK, Gaudio PA. Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. Ocul Immunol Inflamm 2008; 16:103-105. (Pubitemid 351874133)
17. Khalifa Y, Loh AR, Acharya NR. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2009; 17:431-433.
18. Da Silva GR, da Silva Cunha A Jr, Ayres E, Orefice RL. Effect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugs. J Mater Sci Mater Med 2009; 20:481-487.
19. Hardwig PW, Pulido JS, Erie JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006; 142:883-885. (Pubitemid 44584144)
20. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009; 116:797-801.
21. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007; 114:1574 e1
22. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 2008; 28:41-45.
23. Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye 2009; 23:1812-1818.
24. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010; 30:1530-1535.
25. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4:525-533.
26. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005; 80:249-258.
27. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110:681-686. (Pubitemid 36520063)
28. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 2002; 10:239-246. (Pubitemid 36886366)
29. Menezo V, Lau C, Comer M, Lightman S. Clinical outcome of chronic immunosuppression in patients with noninfectious uveitis. Clin Exp Ophthalmol 2005; 33:16-21. (Pubitemid 40330970)
30. Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm 2003; 11:29-38. (Pubitemid 36918643)
31. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ 2000; 320:555-558.
32. Maca SM, Abela-Formanek C, Kiss CG, et al. Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Exp Ophthalmol 2009; 37:389-396.
33. Habot-Wilner Z, Sallam A, Pacheco PA, et al. Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol 2010; 21:56-61.
34. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther 2007; 23:395-401. (Pubitemid 350195065)
35. Jonas JB. Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol 2004; 137:367-368. (Pubitemid 38221022)
36. Karacorlu M, Arf Karacorlu S, Ozdemir H. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome. Eur J Ophthalmol 2006; 16:481-483. (Pubitemid 44049297)
37. Sallam A, Taylor SRJ, Habot-Wilner Z, et al. Outcome of repeat intravitreal triamcinolone acetonide injections in uveitic macular edema. Acta Ophthalmol (in press).
38. Gillies MC, Islam FM, Zhu M, et al. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007; 91:1323-1326. (Pubitemid 47492866)
39. Das-Bhaumik RG, Jones NP. Low-dose intraocular triamcinolone injection for intractable macular oedema and inflammation in patients with uveitis. Eye 2006; 20:934-937. (Pubitemid 44210188)
40. Nguyen QD, Callanan D, Dugel P, et al. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina 2006; Suppl:1-16. (Pubitemid 44622737)
41. Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol 2008; 145:667-675.
42. Yeh S, Cebulla CM, Witherspoon SR, et al. Management of fluocinolone implant dissociation during implant exchange. Arch Ophthalmol 2009; 127:1218-1221.
43. Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004; 20:269-275. (Pubitemid 38849806)
44. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007; 125:1478-1485. (Pubitemid 350106679)
45. Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010; 117:567-575; 75 e1.
46. Hebson CB, Srivastava SK. A functional, nonfunctioning retisert implant. Ocul Immunol Inflamm 2011; 19:210-211.
47. Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol 2007; 143:334-335. (Pubitemid 46136145)
48. Ramaiya KJ, Rao PK. Herpetic necrotizing retinitis following fluocinolone acetonide intravitreal implant. Ocul Immunol Inflamm 2011; 19:72-74.
49. Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010; 149:550 e10-561 e10.
50. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997; 115:1152-1156. (Pubitemid 27387951)
51. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109:1709-1716. (Pubitemid 35012013)
52. Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001; 132:794-796. (Pubitemid 33031303)
53. Huang S, Robinson JB, Deguzman A, et al. Blockade of nuclear factor-kappa B signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000; 60:5334-5339.
54. Van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 2006; 142:192-194. (Pubitemid 43946800)
55. Cohen T, Nahari D, Cerem LW, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271:736-741. (Pubitemid 26034921)
56. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148:303 e2-309 e2.
57. Lasave AF, Zeballos DG, El-Haig WM, et al. Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 2009; 17:423-430.
58. Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011; 31:111-118.
59. Soheilian M, Rabbanikhah Z, Ramezani A, et al. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 2010; 26:199-206.
60. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 2009; 19:622-629.
61. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431. (Pubitemid 44511557)
62. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444. (Pubitemid 44511558)
63. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004; 138:648-650. (Pubitemid 39420497)
64. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sightthreatening ocular inflammation in Adamantiadis-Behçet disease. Ann Intern Med 2004; 140:404-406. (Pubitemid 38268925)
65. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sightthreatening panuveitis in Behçet's disease. Lancet 2001; 358:295-296. (Pubitemid 32738970)
66. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007; 27:399-413. (Pubitemid 46624278)
67. Giganti M, Beer PM, Lemanski N, et al. Adverse events after intravitreal infliximab (Remicade). Retina 2010; 30:71-80.
68. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011; 31:298-303.
69. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well designed trial. Retina 2010; 30:1-5.
70. Tsilimbaris M, Diakonis VF, Naoumidi I, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol 2009; 247:1119-1125.
71. Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117:1612-1616.
72. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5:1039-1046.
73. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010; 117:1393 e3-1399 e3.
74. Barnett PJ. Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled release platform). Conf Proc IEEE Eng Med Biol Soc 2009; 2009:3087-3090.
75. Ohia EO, Mancino M, Kulkarni PS. Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits. J Ocul Pharmacol 1992; 8:295-307. (Pubitemid 23040165)